Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 13 | 2025 | 267 | 4.150 |
Why?
|
| Brachytherapy | 9 | 2025 | 92 | 2.980 |
Why?
|
| Radiosurgery | 4 | 2020 | 147 | 1.850 |
Why?
|
| Genital Neoplasms, Female | 2 | 2024 | 47 | 1.440 |
Why?
|
| Radiation Injuries | 4 | 2025 | 165 | 1.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2025 | 106 | 1.090 |
Why?
|
| Neoplasms | 5 | 2022 | 3027 | 0.980 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 2764 | 0.970 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2025 | 874 | 0.970 |
Why?
|
| Radiotherapy | 5 | 2020 | 148 | 0.910 |
Why?
|
| Radiation Oncology | 1 | 2022 | 28 | 0.790 |
Why?
|
| Cultural Diversity | 1 | 2022 | 71 | 0.780 |
Why?
|
| Chemoradiotherapy | 6 | 2025 | 130 | 0.740 |
Why?
|
| Precision Medicine | 1 | 2024 | 356 | 0.690 |
Why?
|
| Radiotherapy Dosage | 3 | 2020 | 231 | 0.690 |
Why?
|
| Pain, Procedural | 1 | 2020 | 9 | 0.690 |
Why?
|
| Musculoskeletal System | 1 | 2020 | 19 | 0.670 |
Why?
|
| Anesthesia, Local | 1 | 2020 | 45 | 0.670 |
Why?
|
| Occupational Injuries | 1 | 2020 | 12 | 0.670 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2020 | 35 | 0.660 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 61 | 0.650 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 255 | 0.640 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 86 | 0.630 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 76 | 0.630 |
Why?
|
| Analgesics | 1 | 2020 | 134 | 0.630 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 50 | 0.630 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1070 | 0.620 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 114 | 0.610 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 1386 | 0.610 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 267 | 0.590 |
Why?
|
| Codeine | 1 | 2018 | 23 | 0.590 |
Why?
|
| Hydrocodone | 1 | 2018 | 36 | 0.580 |
Why?
|
| Hormones | 1 | 2019 | 195 | 0.580 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 164 | 0.570 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1153 | 0.570 |
Why?
|
| Lung Injury | 1 | 2019 | 123 | 0.560 |
Why?
|
| Acetaminophen | 1 | 2018 | 100 | 0.540 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 366 | 0.520 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 480 | 0.510 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 271 | 0.510 |
Why?
|
| Female | 30 | 2025 | 71659 | 0.490 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2024 | 91 | 0.450 |
Why?
|
| Androgen Antagonists | 1 | 2015 | 131 | 0.440 |
Why?
|
| Humans | 37 | 2025 | 133932 | 0.440 |
Why?
|
| Databases, Factual | 4 | 2020 | 1240 | 0.430 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 272 | 0.430 |
Why?
|
| United States | 9 | 2022 | 11683 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 699 | 0.410 |
Why?
|
| Quality of Life | 2 | 2022 | 2134 | 0.400 |
Why?
|
| Middle Aged | 15 | 2025 | 29394 | 0.390 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 679 | 0.380 |
Why?
|
| Aged | 11 | 2025 | 21730 | 0.380 |
Why?
|
| SEER Program | 3 | 2020 | 224 | 0.360 |
Why?
|
| Adult | 13 | 2025 | 31946 | 0.350 |
Why?
|
| Patient Positioning | 1 | 2010 | 57 | 0.310 |
Why?
|
| Safety-net Providers | 2 | 2022 | 62 | 0.300 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 1409 | 0.300 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17481 | 0.300 |
Why?
|
| Skin | 2 | 2019 | 551 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 404 | 0.290 |
Why?
|
| Family Planning Services | 2 | 2024 | 39 | 0.270 |
Why?
|
| Propensity Score | 2 | 2018 | 258 | 0.270 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1623 | 0.240 |
Why?
|
| Survival Rate | 3 | 2020 | 2207 | 0.240 |
Why?
|
| Vulvar Neoplasms | 1 | 2025 | 24 | 0.240 |
Why?
|
| Young Adult | 5 | 2019 | 9887 | 0.240 |
Why?
|
| Hydronephrosis | 1 | 2025 | 38 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7204 | 0.230 |
Why?
|
| Organ Sparing Treatments | 1 | 2025 | 42 | 0.230 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 920 | 0.230 |
Why?
|
| Cisplatin | 3 | 2025 | 287 | 0.230 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 175 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1315 | 0.220 |
Why?
|
| Physicians, Women | 1 | 2024 | 50 | 0.210 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2025 | 21 | 0.210 |
Why?
|
| Lymph Nodes | 1 | 2005 | 397 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2017 | 479 | 0.210 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2022 | 11 | 0.200 |
Why?
|
| Oncologists | 1 | 2022 | 29 | 0.190 |
Why?
|
| Anthracyclines | 1 | 2021 | 44 | 0.190 |
Why?
|
| Infertility | 1 | 2022 | 82 | 0.180 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 310 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 377 | 0.180 |
Why?
|
| Urban Population | 1 | 2022 | 240 | 0.180 |
Why?
|
| Promethazine | 1 | 2020 | 5 | 0.170 |
Why?
|
| Hydromorphone | 1 | 2020 | 11 | 0.170 |
Why?
|
| Minority Groups | 1 | 2022 | 255 | 0.170 |
Why?
|
| Lorazepam | 1 | 2020 | 12 | 0.170 |
Why?
|
| Age Factors | 3 | 2019 | 2977 | 0.170 |
Why?
|
| Antiemetics | 1 | 2020 | 23 | 0.170 |
Why?
|
| Organs at Risk | 1 | 2020 | 40 | 0.170 |
Why?
|
| Ibuprofen | 1 | 2020 | 43 | 0.170 |
Why?
|
| Anti-Anxiety Agents | 1 | 2020 | 77 | 0.160 |
Why?
|
| Emotions | 1 | 2022 | 364 | 0.160 |
Why?
|
| Rectum | 1 | 2020 | 113 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 8 | 0.160 |
Why?
|
| Radiation Pneumonitis | 1 | 2019 | 12 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 144 | 0.160 |
Why?
|
| Esomeprazole | 1 | 2019 | 33 | 0.160 |
Why?
|
| Mastectomy, Radical | 1 | 2019 | 9 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2018 | 1596 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 971 | 0.150 |
Why?
|
| Urinary Bladder | 1 | 2020 | 251 | 0.150 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 6 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2019 | 93 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 38 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 72 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2196 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 110 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2018 | 49 | 0.140 |
Why?
|
| Kidney | 1 | 2025 | 1410 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 401 | 0.140 |
Why?
|
| Fibrosis | 1 | 2019 | 461 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 283 | 0.140 |
Why?
|
| General Surgery | 1 | 2019 | 217 | 0.130 |
Why?
|
| Medicare | 1 | 2020 | 464 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1850 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 360 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 746 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 667 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3990 | 0.120 |
Why?
|
| Male | 8 | 2020 | 65882 | 0.120 |
Why?
|
| Logistic Models | 2 | 2018 | 1909 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1720 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1315 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1304 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 92 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2025 | 5173 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2018 | 13011 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 74 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1789 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2015 | 40 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1354 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 307 | 0.110 |
Why?
|
| Radiography | 2 | 2022 | 826 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 635 | 0.100 |
Why?
|
| Prevalence | 1 | 2020 | 2654 | 0.100 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 42 | 0.100 |
Why?
|
| Carcinoma | 1 | 2015 | 322 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1196 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2022 | 1250 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1599 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6664 | 0.090 |
Why?
|
| Fertility | 2 | 2024 | 267 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1483 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 621 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3695 | 0.080 |
Why?
|
| Electrons | 1 | 2010 | 27 | 0.080 |
Why?
|
| Pain | 1 | 2013 | 478 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3689 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 5074 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 458 | 0.070 |
Why?
|
| Risk Factors | 2 | 2020 | 11087 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 3220 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 634 | 0.060 |
Why?
|
| Child | 3 | 2022 | 25739 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2005 | 353 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 343 | 0.060 |
Why?
|
| Sexism | 1 | 2024 | 43 | 0.060 |
Why?
|
| Adolescent | 2 | 2019 | 20536 | 0.050 |
Why?
|
| Infant | 1 | 2019 | 13161 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2005 | 148 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 81 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2019 | 14800 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 1711 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2024 | 153 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 244 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 45 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3849 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 739 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 205 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 2 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 132 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 30 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 711 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 104 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 130 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 3393 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 319 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 368 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 496 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 168 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6588 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1735 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1139 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 604 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 333 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2013 | 10 | 0.030 |
Why?
|
| Infusions, Spinal | 1 | 2013 | 2 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 962 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 133 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1833 | 0.020 |
Why?
|
| Reference Standards | 1 | 2013 | 245 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1911 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1607 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 201 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4821 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7523 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4776 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 3072 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5505 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 18911 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 36398 | 0.010 |
Why?
|